多拉韦林在真实世界HIV感染者中的群体药代动力学分析
本研究基于瑞士洛桑大学医院2019至2023年TDM项目中146名HIV感染者的174份多拉韦林浓度数据,采用NONMEM进行群体药代动力学分析与蒙特卡洛模拟。结果显示强效CYP3A4抑制剂使多拉韦林清除率降低50%,年龄也有一定影响,但鉴于多拉韦林耐受性良好,上述情况下可能无需调整剂量。
要点
- 强效CYP3A4抑制剂使多拉韦林清除率降低50%,解释59%的清除率个体间变异。
- 80岁较55岁HIV感染者多拉韦林清除率降低30%。
- 合用强效CYP3A4抑制剂时稳态谷浓度和中位峰浓度分别升高2.8倍和1.6倍。
核心结论
- 强效CYP3A4抑制剂和年龄影响多拉韦林药代动力学,但鉴于其良好耐受性,上述情况下可能无需调整剂量。
- TDM仍主要用于肝损伤、疑似依从性差或妊娠等特定临床情况。
研究设计与样本
- 研究纳入瑞士洛桑大学医院2019至2023年TDM项目中146名HIV感染者的174份多拉韦林浓度数据。
- 采用NONMEM进行群体药代动力学分析及蒙特卡洛模拟, demographic、临床信息及合并用药在常规SHCS随访(每3-6个月)中记录。
主要发现
- 一室模型加一级吸收和线性消除最佳描述多拉韦林药代动力学。
- 强效CYP3A4抑制剂使多拉韦林清除率降低50%,并解释59%的清除率个体间变异。
- 80岁较55岁HIV感染者多拉韦林清除率降低30%。
- 合用强效CYP3A4抑制剂时,模型模拟预测稳态谷浓度中位数升高2.8倍,峰浓度中位数升高1.6倍。
关键数值与推荐
- 强效CYP3A4抑制剂使多拉韦林清除率降低50%。
- 80岁较55岁HIV感染者多拉韦林清除率降低30%。
- 强效CYP3A4抑制剂解释59%的清除率个体间变异。
- 合用强效CYP3A4抑制剂时稳态谷浓度中位数升高2.8倍,峰浓度中位数升高1.6倍。
临床怎么用
- 合用强效CYP3A4抑制剂或高龄患者中,多拉韦林暴露升高但通常耐受性良好,可能无需常规调整剂量。
- TDM可考虑用于肝损伤、疑似依从性差或妊娠等特定临床情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The pharmacokinetics of doravirine has been studied in clinical trials but not in real-world settings. Our study aims to characterize and identify factors influencing doravirine (a CYP3A4 substrate) pharmacokinetics in real-world people with HIV (PWH). METHODS: A total of 174 doravirine concentrations measured in 146 PWH followed up in the therapeutic drug monitoring (TDM) program at the University Hospital of Lausanne (Switzerland) between 2019 and 2023 were included in the analysis. Demographic data, clinical information and comedications were recorded during the routine SHCS visits (every 3-6 months). Population pharmacokinetic analysis and Monte Carlo simulations to investigate the clinical significance of the covariates retained in the final model were performed using NONMEM. RESULTS: A one-compartment model with first-order absorption and linear elimination best described doravirine pharmacokinetics. Potent CYP3A4 inhibitors and, to a lesser extent age, were the only tested covariates to significantly impact doravirine clearance (CL). Potent CYP3A4 inhibitors reduced CL by 50%, and a 30% decrease in CL was observed in an 80-year-old compared with a 55-year-old PWH. The effect of potent CYP3A4 inhibitors was prominent, explaining 59% of between-subject variability in CL. Model-based simulations predicted 2.8-fold and 1.6-fold increases in median steady-state trough and maximum doravirine concentrations, respectively, when a potent CYP3A4 inhibitor was co-administered. CONCLUSIONS: Our findings show that potent CYP3A4 inhibitors and age influence doravirine pharmacokinetics. However, given the good tolerability of doravirine, dosing adjustment of doravirine is probably not mandatory in those situations. TDM remains useful essentially in specific clinical situations, such as hepatic impairment, suspected nonadherence or pregnancy.
引用
- Thoueille P, Delarive L, Cavassini M, et al. Population pharmacokinetic analysis of doravirine in real-world people with HIV. Br J Clin Pharmacol. 2024. PMID: 37994177. doi:10.1111/bcp.15975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。